92 related articles for article (PubMed ID: 11370539)
1. Diagnostic scintigraphy in postoperative staging and follow-up of differentiated thyroid carcinoma.
Casara D; Rubello D
Rays; 2000; 25(2):207-19. PubMed ID: 11370539
[TBL] [Abstract][Full Text] [Related]
2. The use of non-specific tracers in the follow up of differentiated thyroid cancer: results with Tc-99m tetrofosmin whole body scintigraphy.
Lind P; Gallowitsch HJ
Acta Med Austriaca; 1996; 23(1-2):69-75. PubMed ID: 8767519
[TBL] [Abstract][Full Text] [Related]
3. [Diagnosis, treatment and follow-up in the case of differentiated thyroid cancer].
Lind P; Igerc I; Kohlfürst S
Wien Med Wochenschr; 2005 Oct; 155(19-20):429-35. PubMed ID: 16424998
[TBL] [Abstract][Full Text] [Related]
4. Respective roles of thyroglobulin, radioiodine imaging, and positron emission tomography in the assessment of thyroid cancer.
Lind P; Kohlfürst S
Semin Nucl Med; 2006 Jul; 36(3):194-205. PubMed ID: 16762610
[TBL] [Abstract][Full Text] [Related]
5. Follow-up of differentiated thyroid cancer: what is the value of FDG and sestamibi in the diagnostic algorithm?
Dietlein M; Scheidhauer K; Voth E; Theissen P; Schicha H
Nuklearmedizin; 1998 Jan; 37(1):12-7. PubMed ID: 9467164
[TBL] [Abstract][Full Text] [Related]
6. 99mTc-sestamibi and 131I whole-body scintigraphy and initial serum thyroglobulin in the management of differentiated thyroid carcinoma.
Ng DC; Sundram FX; Sin AE
J Nucl Med; 2000 Apr; 41(4):631-5. PubMed ID: 10768563
[TBL] [Abstract][Full Text] [Related]
7. Thyroglobulin and low-dose iodine-131 and technetium-99m-tetrofosmin whole-body scintigraphy in differentiated thyroid carcinoma.
Gallowitsch HJ; Mikosch P; Kresnik E; Unterweger O; Gomez I; Lind P
J Nucl Med; 1998 May; 39(5):870-5. PubMed ID: 9591591
[TBL] [Abstract][Full Text] [Related]
8. Nuclear medicine imaging procedures in differentiated thyroid carcinoma patients with negative iodine scan.
Rubello D; Saladini G; Carpi A; Casara D
Biomed Pharmacother; 2000 Jul; 54(6):337-44. PubMed ID: 10989970
[TBL] [Abstract][Full Text] [Related]
9. Nuclear medicine approaches in the monitoring of thyroid cancer patients.
Sergieva S; Hadjieva T; Doldurova M; Stefanova S; Dudov A
J BUON; 2006; 11(4):511-8. PubMed ID: 17309186
[TBL] [Abstract][Full Text] [Related]
10. [Diagnostic modalities in patients affected by differentiated thyroid carcinoma with high thyroglobulin levels and total body Iodium-131 negative: PET/CT use after recTSH].
Biscontini G; Possa M; Sara R; Milella M; Rossetti C
Minerva Endocrinol; 2004 Dec; 29(4):151-60. PubMed ID: 15765025
[TBL] [Abstract][Full Text] [Related]
11. Technetium-99m-tetrofosmin whole-body scintigraphy in the follow-up of differentiated thyroid carcinoma.
Lind P; Gallowitsch HJ; Langsteger W; Kresnik E; Mikosch P; Gomez I
J Nucl Med; 1997 Mar; 38(3):348-52. PubMed ID: 9074515
[TBL] [Abstract][Full Text] [Related]
12. Technetium-99m tetrofosmin uptake in insular thyroid carcinoma. A comparison with iodine-131.
Degirmenci B; Aydin A; Comlekci A; Ozdogan O; Bekis R
Clin Nucl Med; 2003 May; 28(5):385-8. PubMed ID: 12702934
[TBL] [Abstract][Full Text] [Related]
13. Thyroglobulin radioimmunoassay and 131I scintigraphy in patients with differentiated thyroid carcinoma.
Lindegaard MW; Paus E; Høie J; Kullman G; Stenwig AE
Acta Chir Scand; 1988 Feb; 154(2):141-5. PubMed ID: 3354295
[TBL] [Abstract][Full Text] [Related]
14. Detection of residual and recurrent thyroid cancer by radionuclide imaging.
Maxon HR
Thyroid; 1999 May; 9(5):443-6. PubMed ID: 10365674
[TBL] [Abstract][Full Text] [Related]
15. Tc-99m-tetrofosmin scintigraphy: an alternative scintigraphic method for following up differentiated thyroid carcinoma--preliminary results.
Gallowitsch HJ; Kresnik E; Mikosch P; Pipam W; Gomez I; Lind P
Nuklearmedizin; 1996 Dec; 35(6):230-5. PubMed ID: 8976503
[TBL] [Abstract][Full Text] [Related]
16. The use of imaging studies in the diagnosis and management of thyroid cancer and hyperparathyroidism.
James C; Starks M; MacGillivray DC; White J
Surg Oncol Clin N Am; 1999 Jan; 8(1):145-69. PubMed ID: 9824366
[TBL] [Abstract][Full Text] [Related]
17. Recombinant human TSH changes the multidisciplinary approach to patients with differentiated thyroid carcinoma. Two-year experience.
Giusti M; Zoccola R; Guazzini B; Molinari E; Valenti S; Villa G; Bertolazzi L; Minuto F
Minerva Endocrinol; 2003 Sep; 28(3):191-203. PubMed ID: 14605601
[TBL] [Abstract][Full Text] [Related]
18. Detecting metastatic neck lymph nodes in papillary thyroid carcinoma by 18F-2-deoxyglucose positron emission tomography and Tc-99m tetrofosmin single photon emission computed tomography.
Wu YJ; Wu HS; Yen RF; Shen YY; Kao CH
Anticancer Res; 2003; 23(3C):2973-6. PubMed ID: 12926147
[TBL] [Abstract][Full Text] [Related]
19. Clinical and laboratory follow-up in differentiated thyroid carcinoma.
Maussier ML; Danese D; D'Errico G; Garganese MC; Pontecorvi A; Lemmo G
Rays; 2000; 25(2):239-44. PubMed ID: 11370541
[TBL] [Abstract][Full Text] [Related]
20. 99mTc-sestamibi radio-guided surgery of loco-regional 131Iodine-negative recurrent thyroid cancer.
Rubello D; Salvatori M; Casara D; Piotto A; Toniato A; Gross MD; Al-Nahhas A; Muzzio PC; Pelizzo MR
Eur J Surg Oncol; 2007 Sep; 33(7):902-6. PubMed ID: 17267163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]